EA202090322A1 - Selective Protein-Arginine-Methyl Transferase 5 Inhibitors (PRMT5) - Google Patents

Selective Protein-Arginine-Methyl Transferase 5 Inhibitors (PRMT5)

Info

Publication number
EA202090322A1
EA202090322A1 EA202090322A EA202090322A EA202090322A1 EA 202090322 A1 EA202090322 A1 EA 202090322A1 EA 202090322 A EA202090322 A EA 202090322A EA 202090322 A EA202090322 A EA 202090322A EA 202090322 A1 EA202090322 A1 EA 202090322A1
Authority
EA
Eurasian Patent Office
Prior art keywords
prmt5
arginine
inhibitors
methyl transferase
selective protein
Prior art date
Application number
EA202090322A
Other languages
Russian (ru)
Inventor
Хуан Луэнго
Хун Линь
Рупа Шетти
Майкл Хокинз
Original Assignee
Прельюд Терапьютикс, Инкорпорейтед
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Прельюд Терапьютикс, Инкорпорейтед filed Critical Прельюд Терапьютикс, Инкорпорейтед
Priority claimed from PCT/US2018/046057 external-priority patent/WO2019032859A1/en
Publication of EA202090322A1 publication Critical patent/EA202090322A1/en

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/70—Carbohydrates; Sugars; Derivatives thereof
    • A61K31/7042—Compounds having saccharide radicals and heterocyclic rings
    • A61K31/7052—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides
    • A61K31/706—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides containing six-membered rings with nitrogen as a ring hetero atom
    • A61K31/7064—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides containing six-membered rings with nitrogen as a ring hetero atom containing condensed or non-condensed pyrimidines
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A61P35/02—Antineoplastic agents specific for leukemia
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D487/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00
    • C07D487/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00 in which the condensed system contains two hetero rings
    • C07D487/04—Ortho-condensed systems
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D519/00—Heterocyclic compounds containing more than one system of two or more relevant hetero rings condensed among themselves or condensed with a common carbocyclic ring system not provided for in groups C07D453/00 or C07D455/00
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07H—SUGARS; DERIVATIVES THEREOF; NUCLEOSIDES; NUCLEOTIDES; NUCLEIC ACIDS
    • C07H19/00—Compounds containing a hetero ring sharing one ring hetero atom with a saccharide radical; Nucleosides; Mononucleotides; Anhydro-derivatives thereof
    • C07H19/02—Compounds containing a hetero ring sharing one ring hetero atom with a saccharide radical; Nucleosides; Mononucleotides; Anhydro-derivatives thereof sharing nitrogen
    • C07H19/04—Heterocyclic radicals containing only nitrogen atoms as ring hetero atom
    • C07H19/14—Pyrrolo-pyrimidine radicals

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Animal Behavior & Ethology (AREA)
  • Molecular Biology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Medicinal Chemistry (AREA)
  • Biochemistry (AREA)
  • Epidemiology (AREA)
  • Genetics & Genomics (AREA)
  • Biotechnology (AREA)
  • Engineering & Computer Science (AREA)
  • Hematology (AREA)
  • Oncology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Plural Heterocyclic Compounds (AREA)

Abstract

Изобретение относится к соединениям формулы (I). Описаны фармацевтические композиции, содержащие соединения формулы (I), а также способы их использования и получения.The invention relates to compounds of formula (I). Pharmaceutical compositions containing compounds of formula (I) are described, as well as methods for their use and preparation.

EA202090322A 2018-04-30 2018-08-09 Selective Protein-Arginine-Methyl Transferase 5 Inhibitors (PRMT5) EA202090322A1 (en)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US201862664442P 2018-04-30 2018-04-30
PCT/US2018/046057 WO2019032859A1 (en) 2017-08-09 2018-08-09 Selective inhibitors of protein arginine methyltransferase 5 (prmt5)

Publications (1)

Publication Number Publication Date
EA202090322A1 true EA202090322A1 (en) 2020-06-26

Family

ID=71138830

Family Applications (1)

Application Number Title Priority Date Filing Date
EA202090322A EA202090322A1 (en) 2018-04-30 2018-08-09 Selective Protein-Arginine-Methyl Transferase 5 Inhibitors (PRMT5)

Country Status (1)

Country Link
EA (1) EA202090322A1 (en)

Similar Documents

Publication Publication Date Title
PH12021551065A1 (en) Fused ring compounds
EA202092896A1 (en) HETEROCYCLIC AND HETEROARYL COMPOUNDS FOR THE TREATMENT OF GENTINGTON'S DISEASE
CR20210083A (en) Fused ring compounds
MX2020001598A (en) Selective inhibitors of protein arginine methyltransferase 5 (prmt5).
EA202091267A1 (en) 1,2,4-OXADIAZOLIC COMPOUNDS AS INHIBITORS OF CD47 SIGNAL PATHWAYS
EA202092899A1 (en) HETEROARYL COMPOUNDS FOR THE TREATMENT OF GENTINGTON'S DISEASE
EA201990495A1 (en) BIARY COMPOUNDS APPLICABLE AS IMMUNOMODULATORS
EA201990851A1 (en) NEW CARBANUCLEOSIDE ANALOGUES REPLACED BY MONOCYCLIC AND BICYCLIC RING SYSTEM FOR USE AS PRMT5 INHIBITORS
EA201890573A1 (en) NEW 6-6-BICYCLIC AROMATIC RING SUBSTITUTED NUCLEOSIDE ANALOGUES FOR APPLICATION AS PRMT5 INHIBITORS
EA202091479A1 (en) ARYL- AND HETEROARYL-SUBSTITUTED INDOL COMPOUNDS
MX2021005463A (en) Spiro-sulfonamide derivatives as inhibitors of myeloid cell leukemia-1 (mcl-1) protein.
EA201890086A1 (en) 1,4-substituted derivatives of piperidine
EA201890247A1 (en) DEZOXYURIDINTRIPHIPHPHATASI INHIBITORS CONTAINING HYDANTOIN
EA201691302A1 (en) NEW HETEROCYCLIC COMPOUNDS
EA201591965A1 (en) Derivatives of benzimidazole as bromodomain inhibitors
EA202091480A1 (en) AMINOINDOL COMPOUNDS SUITABLE AS TLR INHIBITORS
EA201890592A1 (en) LIQUID PHARMACEUTICAL COMPOSITIONS CONTAINING SGLT-2 INHIBITORS
MX2020009234A (en) Heteroaryl compounds as type ii irak inhibitors and uses hereof.
EA201692268A1 (en) PHOSPHATIDYLINOSITOL-3-KINASE INHIBITORS
EA201891379A1 (en) BLUTON THYROSIN KINASE INHIBITORS AND METHODS OF THEIR USE
EA201891378A1 (en) POLYCYCLIC COMPOUNDS AS BRUTTON TYROSINKINASE INHIBITORS
EA201991700A1 (en) SELECTIVE INHIBITORS JAK1
EA202190055A1 (en) PYRAZOL DERIVATIVES AS MALT1 INHIBITORS
EA201792425A1 (en) TRICYCLIC COMPOUNDS AND THEIR APPLICATION AS PHOSPHODYSTERASE INHIBITORS
EA202191478A1 (en) HETEROAROMATIC COMPOUNDS AS VANIN INHIBITORS